VERU Veru Inc.

2.1
+0.02  (+1%)
Previous Close 2.08
Open 2.09
Price To Book 3.97
Market Cap 136,755,922
Shares 65,038,247
Volume 34,801
Short Ratio
Av. Daily Volume 114,776
Stock charts supplied by TradingView

NewsSee all news

  1. Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

    -- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer

  2. Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

    MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

  3. Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

    MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due fall of 2019.
Zuclomiphene citrate
Hot flashes
NDA filing due summer 2020.
Tadalafil and Finasteride combo
Benign prostatic hyperplasia (BPH)
Phase 1b initiation announced January 22, 2019 with data due later in 2019 or early 2020.
VERU-111 (bisindole)
Prostate cancer
Phase 2 trial to be initiated early 2020.
VERU-100
Prostate cancer

Latest News

  1. Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

    -- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer

  2. Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

    MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

  3. Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

    MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today